HomeStrategyA Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund... Strategy A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs Strategy October 7, 2026 0 65 FacebookXPinterestWhatsApp The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale. FacebookXPinterestWhatsApp Cody Previous articleAffirm partners with Ant International’s Antom to bring pay-over-time to US customersNext articleAfter $21M assessment uproar, Brickell association says contractor overbilled, left work undone RELATED ARTICLES Strategy Reddit Is About to Make Its Website Worse to Protect It From AI Strategy I’ve Sat on 23 Boards. Here’s What Founders Get Wrong When They Hire a CEO and Step Back Strategy Employee engagement in U.S. hits lowest point in 15 years Strategy Inside giant homebuilder D.R. Horton’s bet on robotic homebuilding Must Read Brakes built for speed: Why least privilege lets monday.com’s AI teams move faster Tech Monday.com bets on deployment experts to turn AI agents into real returns Tech Reddit Is About to Make Its Website Worse to Protect It From AI Strategy AI architecture startup Dream launches with $17M in funding Tech Intel shares plummet more than 20% following weak guidance blamed on PC market slowdown Tech